Cemdisiran regulatory submissions accepted for review by FDA and EMA for the treatment of generalized myasthenia gravis

Regeneron has announced that both the US Food and Drug Administration and the European Medicines Agency have accepted regulatory applications for cemdisiran for the treatment of adult patients with generalized myasthenia gravis who carry anti-acetylcholine receptor antibody positivity. The FDA will conduct its review of the New Drug Application under Priority Review, following the use of a Priority Review Voucher, with a target action date set for November 2026. A decision from the European Commission is expected to follow in the latter half of 2027, and a regulatory filing in Japan is being prepared for early 2027.

Both submissions are built on data from the Phase 3 NIMBLE trial, which assessed cemdisiran administered subcutaneously every 12 weeks in adults with symptomatic generalized myasthenia gravis, who were permitted to continue receiving standard of care immunosuppressants at the treating physician’s discretion. Standing as one of the largest interventional generalized myasthenia gravis trials conducted globally, NIMBLE’s complete dataset was simultaneously published in The Lancet and presented at the American Academy of Neurology Annual Meeting in April 2026.

Myasthenia gravis is a rare, chronic autoimmune condition in which abnormal anti-acetylcholine receptor antibodies trigger activation of the complement system, including C5, disrupting the signals passing between nerves and muscles and producing debilitating and potentially life-threatening weakness. Across the world, an estimated 150 to 200 people in every million are affected, with the disease touching approximately 85,000 individuals in the US alone. The condition typically first presents through ocular symptoms, yet around 85% of those affected go on to experience progression into additional areas of the body, at which point it is classified as generalized myasthenia gravis. At this stage, muscle groups throughout the body become implicated, bringing with them profound fatigue alongside difficulties in facial expression, speech, swallowing, and movement. Many patients with generalized myasthenia gravis continue to face significant challenges in managing their condition, navigating treatments that address only symptoms rather than underlying disease, the sustained demands of long-term immunosuppressant use, incomplete responses, and the gradual erosion of treatment effectiveness over time, all of which can take a considerable toll on quality of life.

---

---

Related Topics and Keywords

Cemdisiran, generalized myasthenia gravis, Regeneron